<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Kim French

20+ years of progressive medical device and biologics marketing and sales experience in orthopedic biological implants, cellular technologies and biopharmaceuticals. Most recent experience includes President, Trilogy Consulting and Marketing and Sales Management roles at AlloSource and Terumo BCT.
Find me on:

Recent Posts

Q219 OrthoBio Market Recap: Strong Performance

Posted by Kim French on 9/12/19 10:00 AM

Sales strategy, market reach and evidence-based medicine drives strong Orthobiologics performance

SmartTRAK reports that Q219 performance in the OrthoBio market was strong, up 6% YoY, exceeding SmartTRAK expectations. As expected, Medtronic was the overall OrthoBio market leader, followed by DePuy Synthes and Stryker. Overall, all OrthoBio technologies grew year-over-year except for Spinal Constructs, Soft Tissue Augmentation and Synthetic Cartilage. Although the Spine market has stabilized, Spinal Constructs continues to slowly lose share due to...

Among the many topics covered in the Q219 OrthoBio Market Recap* are:

Read More

Topics: Orthopedics

SmartTRAK's Q418/FY18 OrthoBio Market Recap

Posted by Kim French on 4/8/19 2:00 PM

Advanced, higher priced biologics push the US OrthoBio Market higher

Based on Q418/FY18  SmartTRAK Financial Dashboard reporting:
  • US Bone Replacement grew +2.3% YoY, with FY18 revenues up +2.7%.
  • US Cartilage Replacement increased 55.7% YoY, with FY18 revenues up 34.7%.
  • US Soft Tissue Augmentation grew 2.3%, with FY18 revenues growing 9.2%.
  • US Tendon Allografts posted an 8.4% YoY increase, with FY18 revenues up +3.9% YoY
  • US Meniscal Implant market, with robust growth, was up 15.6% YoY for Q418 with FY18 revenues increasing by 3.0%.

Among the many topics covered in the Q418/FY18 OrthoBio Market Recap are:

Read More

Topics: Orthopedics

Advanced Therapies: SmartTRAK Interviews  Robert Keller, CSO of Axolotl Biologix

Posted by Kim French on 2/12/19 10:57 AM

Stem cell “secretome” is the latest advancement in regenerative medicine. Will it become the heart of tissue regeneration? SmartTRAK interviewed Dr. Robert Keller, Ph.D, Chief Science Officer of Axolotl Biologix to learn more about the Company’s platform and future plans.

The core of regenerative medicine and leveraging the abilities of stem cells and their products to repair diseased or damaged tissues has focused in two main areas, harvesting progenitor cells and the “paracrine effect” of the stem cell secretome.

Recent studies suggest that the benefits of stem cell therapy and the underlying mechanism of repair might relate more to a paracrine modulatory effect rather than the replacement of damaged cells at the site. The secreted factors from the transplanted stems cells have been shown to trigger the patient's own cells to repair the tissue themselves.

One company that is harnessing the power of the stem cell secretome is Axolotl Biologics. Started in 2016, Axolotl Biologics offers human amnion-derived mesenchymal stromal cell (hAMSCs) conditioned medium that contains hAMSCs paracrine factors which can be used in various applications in orthopedics, wound care, pain management, ophthalmology, cardiovascular and cosmetics.

At the 6th ICRS Summit, Bio-Orthopaedics in Sports Medicine, held in San Diego, January 17 and 18, 2019, SmartTRAK caught up with Axolotl Biologix’ Chief Science Officer, Robert Keller, Ph.D. to discuss regenerative medicine and the Company’s progress.

Click on the video below to view the fascinating interview,  scroll down to read a transcript of the interview or download a PDF of the interview by clicking the link below.

Read More

Topics: Orthopedics

Q318 OrthoBio Market Recap: Acquisitions and Partnerships Rule

Posted by Kim French on 12/14/18 2:28 PM

Acquisitions and Partnerships are Highpoints in Q318

SmartTRAK reports that the US OrthoBio Market (comprised of Bone Replacement, Cartilage, Soft Tissue and Meniscus) is growing at 4.1% YTD. For Q318, there were no surprises and the segment reached...

Among the many topics covered in the Q318 OrthoBio Market Recap are:

Read More

Topics: Orthopedics

Q218 OrthoBio Market Recap: Ortho Remains Strong

Posted by Kim French on 8/30/18 12:04 PM

Irrespective of Market Challenges, Orthobiologics Remain Strong

While SmartTRAK saw a strong start in the beginning of the year, Orthobiologics didn’t see the typical Q2 bump. This trend was primarily driven by lower bone replacement revenues. Revenues from the sports medicine segments partially offset the bone replacement declines, with strong performances in Cartilage Replacement and Soft Tissue Augmentation.

Among the many topics covered in the full Q218 Ortho Market Recap are:

Read More

SmartTRAK Interviews Cerapedics:  i-FACTOR, a Novel Bone Graft

Posted by Kim French on 8/15/18 10:07 AM

Cerapedics’ CEO Glen Kashuba and President and COO Jeff Marx, Ph.D. discuss the future of the bone graft substitutes and the uniqueness of i‑FACTOR Peptide Enhanced Bone Graft, a small peptide technology in an interview with Kim French, Sr. Analyst, SmartTRAK Orthbio.

A transcript of SmartTRAK's interview with Glen Kashuba and Jeff Marx is below, or click on the following video to listen to the interview.

Read More

Topics: SmartTRAK News, Orthopedics

SmartTRAK Publication Alert: Q118 OrthoBio Market Recap

Posted by Kim French on 6/19/18 12:54 PM

SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its Q118 OrthoBio Market Recap.

Up 3.4% YoY, the OrthoBio market is off to a good start. Companies that are surpassing growth expectations tend to have differentiated products, focused efforts and incremental pull through from synergistic sales strategies. Market subtleties like reimbursement, pricing pressures and market loss due to newer competition continue to afflict some companies and segments...

Among the many topics covered in the full Q118 OrthoBio Market Recap are: 

Read More

Topics: Orthopedics

SmartTRAK Attending TOBI 2018 in Las Vegas, Nevada

Posted by Kim French on 6/7/18 11:58 AM

SmartTRAK is excited to be attending TOBI 2018 - The 9th Annual PRP & Regenerative Medicine Symposium, Workshops & Cadaver Labs - June 7-9 at Wynn, Las Vegas, Nevada.

Read More

Topics: SmartTRAK News, Regenerative Medicine

SmartTRAK's Final 2017 OrthoBio Market Financial Results

Posted by Kim French on 4/2/18 9:36 AM

Gains in sports medicine, extremities, advanced biologics and joint fluid offset softening spine market

SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 OrthoBio Market Recap and Financial Dashboard.

Despite some challenges in 2017, the US OrthoBio market finished strong, growing 5.3% to $3.46B. Gains in Sports Medicine, Extremities, Advanced Biologics and Joint Fluid countered the softening Spine market and lower growth rates of core biologics. Positive results stemmed from incremental pull through revenue from synergistic sales strategies, entry of new companies, introduction of new products, growth in new surgeon users and use of biologics in non-traditional applications ...

Among the topics covered in the Q417, FY17 OrthoBio Market Recap are:

Read More

Topics: Orthopedics

Regenerative Medicine - Riding a Wave of Innovation

Posted by Kim French on 2/21/18 12:42 PM

Regenerative medicines, the new era of human health, represent a wave of innovation coming to our health care system, approaching much faster than most realize. As of Q217, there were more than 822 companies developing regenerative medicine technologies.

Read More

Topics: Regenerative Medicine, Top Story

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts